Food Manufacturer and Processor Customers Expand Use of PURE's SDC-Based Hard Surface Disinfectant - Seite 2

CUSTOMER COLLABORATION YIELDS NEW PRODUCT

• As a result of close collaboration with its food manufacturing and processing customers, PURE is broadening its product portfolio. In the last 30 days the Company has developed PURE® Multi-Purpose High-Foam Cleaner for in-plant use offering its customers the additional option for their cleaning requirements.
• PURE has also partnered with a leading equipment manufacturer to offer its customers spray and foaming units that are easily portable throughout the facility.
  
  

About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing its proprietary antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control within the food industry. The Company's technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection. As a platform technology, SDC is distinguished from existing products in the marketplace by its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

Forward-looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company's cash position and liquidity requirements, the Company's failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, including to manufacture its products, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission, including our annual report on Form 10-K filed October 24, 2013. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

IR Contacts:
Tom Hemingway
Redwood Investment Group
Email Contact
714-978-4425

Terri MacInnis
Director of IR
Bibicoff + MacInnis, Inc.
Email Contact
818-379-8500

Company Contact:
Peter C. Wulff
CFO & COO
PURE Bioscience, Inc.
Email Contact
619-596-8600 ext.111